Rifaximin 550 MG Oral Tablet [XIFAXAN]
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Wake Forest University Health Sciences
Overview
Rifaximin 550 MG Oral Tablet [XIFAXAN] is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Rifaximin 550 MG Oral Tablet [XIFAXAN] clinical trials
Explore related
Medical disclaimer. This page summarizes research about Rifaximin 550 MG Oral Tablet [XIFAXAN] for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.